CTOs on the Move

Phlexglobal

www.phlexglobal.com

 
Phlexglobal is the leading technology and services organization for clinical and regulatory matters with a focus on helping clients to master their digital agenda via proven AI solutions. Phlexglobal combines software and leading expert services to offer a unique solutions portfolio with easy to achieve automation via data generation that lifts organizations to a new level of effectiveness. PhlexTMF, the company`s Trial Master File software, and Regulatory Solutions including PhlexSubmission for eCTD and CTD, PhlexIDMP, PhlexEVMPD, and PhlexRIM are considered highly innovative in the industry for their out of the box best practices capabilities, use of automation technology, and user-focused ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.phlexglobal.com
  • 400 Chesterfield Parkway Suite 120
    Malvern, PA USA 19355
  • Phone: 484.324.7923

Executives

Name Title Contact Details

Similar Companies

Sinoveda

Sinoveda is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Intellect Neurosciences

Intellect Neurosciences Inc. is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SAFC Pharma

SAFC Pharma is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Community Intervention Services

Argos Therapeutics

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient`s dendritic cells to activate an immune response specific to the patient`s disease.   Argos` most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV. Argos Therapeutics is headquartered in Research Triangle Park, NC. The Company has clinical stage programs in Phase 3 (metastatic renal cell carcinoma), Phase 2b (HIV) and Phase 1a (systemic lupus erythematosus1) development.